CY1118772T1 - Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης - Google Patents

Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης

Info

Publication number
CY1118772T1
CY1118772T1 CY20171100378T CY171100378T CY1118772T1 CY 1118772 T1 CY1118772 T1 CY 1118772T1 CY 20171100378 T CY20171100378 T CY 20171100378T CY 171100378 T CY171100378 T CY 171100378T CY 1118772 T1 CY1118772 T1 CY 1118772T1
Authority
CY
Cyprus
Prior art keywords
caseine
unions
pyridine
new consolidated
suspends
Prior art date
Application number
CY20171100378T
Other languages
English (en)
Inventor
Todd W Butler
Ramalakshmi Y Chandrasekaran
Scot R Mente
Chakrapani Subramanyam
Travis T Wager
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1118772T1 publication Critical patent/CY1118772T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Ενώσεις και φαρμακευτικώς αποδεκτά άλατα των ενώσεων γνωστοποιούνται, όπου οι ενώσεις έχουν τη δομή του Τύπου I˙ και φαρμακευτικώς αποδεκτά άλατα αυτών, όπου Χ, Υ, A, R4, n και R7 είναι όπως ορίζονται στην περιγραφή. Αντίστοιχες φαρμακευτικές συνθέσεις, μέθοδοι αγωγής, μέθοδοι σύνθεσης, και ενδιάμεσα επίσης γνωστοποιούνται.
CY20171100378T 2010-12-20 2017-03-27 Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης CY1118772T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425213P 2010-12-20 2010-12-20
PCT/IB2011/055489 WO2012085721A1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1118772T1 true CY1118772T1 (el) 2017-07-12

Family

ID=45446116

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100378T CY1118772T1 (el) 2010-12-20 2017-03-27 Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης
CY20191100892T CY1122062T1 (el) 2010-12-20 2019-08-21 Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100892T CY1122062T1 (el) 2010-12-20 2019-08-21 Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης

Country Status (24)

Country Link
US (1) US8536164B2 (el)
EP (2) EP3181133B1 (el)
JP (2) JP5684923B2 (el)
KR (1) KR101590236B1 (el)
CN (1) CN103260622B (el)
AR (1) AR084412A1 (el)
AU (1) AU2011346733C1 (el)
CA (1) CA2819961C (el)
CY (2) CY1118772T1 (el)
DK (2) DK3181133T3 (el)
ES (2) ES2623387T3 (el)
HK (1) HK1188145A1 (el)
HR (2) HRP20170484T1 (el)
HU (2) HUE047089T2 (el)
IL (1) IL226948A (el)
LT (2) LT3181133T (el)
MX (1) MX338551B (el)
PL (2) PL3181133T3 (el)
PT (2) PT2654750T (el)
RS (2) RS59098B1 (el)
SG (1) SG190802A1 (el)
SI (2) SI3181133T1 (el)
WO (1) WO2012085721A1 (el)
ZA (1) ZA201303453B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051858A1 (en) * 2009-10-28 2011-05-05 Pfizer Inc. Imidazole derivatives as casein kinase inhibitors
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2014100540A1 (en) * 2012-12-21 2014-06-26 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
WO2015163446A1 (ja) * 2014-04-25 2015-10-29 協和発酵キリン株式会社 イミダゾール化合物の製造方法
JP2017222576A (ja) * 2014-10-31 2017-12-21 石原産業株式会社 有害生物防除剤
CN107365315A (zh) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (zh) * 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
WO2021190615A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
CN111808102B (zh) * 2020-08-03 2021-12-31 南通大学 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法
AU2021345564A1 (en) * 2020-09-17 2023-06-01 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
EP4214214A1 (en) * 2020-09-17 2023-07-26 JANSSEN Pharmaceutica NV Casein kinase 1 delta modulators
CN116888126A (zh) * 2020-12-15 2023-10-13 北京原基华毅生物科技有限公司 一种酪蛋白激酶抑制剂的化合物
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
WO2023241552A1 (en) * 2022-06-14 2023-12-21 Gritscience Biopharmaceuticals Co., Ltd Salt and/or crystal form for compounds as casein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
AP1246A (en) * 1997-05-22 2004-02-07 Searle & Co Substituted pyrazoles as p38 Kinase inhibitors.
DE60021423T2 (de) * 1999-12-21 2006-04-13 Sugen, Inc., San Diego 4-substituierte 7-aza-indolin-2-one und ihre verwendung als proteinkinaseinhibitoren
DK1906965T3 (en) 2005-06-22 2015-08-03 Chemocentryx Inc Azaindazol compounds and methods of use thereof
WO2007140213A1 (en) 2006-05-26 2007-12-06 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011051858A1 (en) * 2009-10-28 2011-05-05 Pfizer Inc. Imidazole derivatives as casein kinase inhibitors

Also Published As

Publication number Publication date
DK2654750T3 (en) 2017-05-01
RS59098B1 (sr) 2019-09-30
CN103260622A (zh) 2013-08-21
CA2819961A1 (en) 2012-06-28
PL3181133T3 (pl) 2019-12-31
EP3181133B1 (en) 2019-07-24
EP2654750B1 (en) 2017-03-08
HRP20170484T1 (hr) 2017-06-02
CN103260622B (zh) 2015-05-13
US8536164B2 (en) 2013-09-17
DK3181133T3 (da) 2019-08-26
HRP20191469T1 (hr) 2019-11-29
HUE032405T2 (en) 2017-09-28
SG190802A1 (en) 2013-07-31
EP3181133A1 (en) 2017-06-21
ZA201303453B (en) 2014-07-30
US20120157440A1 (en) 2012-06-21
SI3181133T1 (sl) 2019-10-30
HUE047089T2 (hu) 2020-04-28
AU2011346733B2 (en) 2015-08-13
PT2654750T (pt) 2017-05-04
KR101590236B1 (ko) 2016-01-29
CY1122062T1 (el) 2020-11-25
EP2654750A1 (en) 2013-10-30
JP5876596B2 (ja) 2016-03-02
LT2654750T (lt) 2017-05-10
SI2654750T1 (sl) 2017-04-26
PL2654750T3 (pl) 2017-07-31
MX2013005833A (es) 2013-07-05
ES2744099T3 (es) 2020-02-21
IL226948A (en) 2017-04-30
JP2014503544A (ja) 2014-02-13
HK1188145A1 (en) 2014-04-25
AR084412A1 (es) 2013-05-15
LT3181133T (lt) 2019-09-25
AU2011346733C1 (en) 2015-12-24
MX338551B (es) 2016-04-20
JP2015107992A (ja) 2015-06-11
JP5684923B2 (ja) 2015-03-18
RS55897B1 (sr) 2017-08-31
ES2623387T3 (es) 2017-07-11
CA2819961C (en) 2015-08-18
PT3181133T (pt) 2019-09-16
WO2012085721A1 (en) 2012-06-28
AU2011346733A1 (en) 2013-07-18
KR20130121126A (ko) 2013-11-05

Similar Documents

Publication Publication Date Title
CY1118772T1 (el) Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1122944T1 (el) Ορισμενες αμινο-πυριμιδινες, συνθεσεις αυτων, και μεθοδοι για χρηση αυτων
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
CY1119177T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
CY1123524T1 (el) Υποκατεστημενα χρωμανια και μεθοδος χρησης
CY1121948T1 (el) Πυρρολο [1,2,f][1,2,4]tpiazineς χρησιμες για θεραπεια λοιμωξεων αναπνευστικου συγκυτιακου ιου
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1120207T1 (el) Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
MY169432A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
CY1119407T1 (el) Διαμορφωτες toy lxr
CY1111705T1 (el) Παραγωγα 2-αζα-δικυκλο[3.1.0]εξανιου ως ανταγωνιστες του υποδοχεα ορεξινης
CY1114112T1 (el) Νεα αρυλαμιδια υποκατεστημενα με πυραζολιο
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
IN2012DN03182A (el)
CY1119022T1 (el) Παραγωγα ν-προπ-2-υνυλ καρβοξαμιδιου και χρηση αυτων ως ανταγωνιστες του trpa1
RS53521B1 (en) PREPARATION AND THERAPY APPLICATIONS (2S, 3R) -N-2 - ((3-pyridinyl) methyl) -1-AZABICYCLO [2.2.2] OCT-3-IL) -3,5-DIFLUOROBENZAMIDE
EP2581372A4 (en) CYANOCHINOLINDERIVATE
CY1122518T1 (el) Καινοφανεις προσδετες υποδοχεα οιστρογονου